Literature DB >> 10943881

Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma.

N A Flavahan1, S Flavahan, Q Liu, S Wu, W Tidmore, C M Wiener, R J Spence, F M Wigley.   

Abstract

OBJECTIVE: Vasospasm and ischemic organ injury are important in the pathogenesis of systemic sclerosis (SSc; scleroderma). The present study was performed to determine whether SSc arterioles have an intrinsic disturbance in vasoconstrictor activity.
METHODS: Skin biopsy samples were obtained from the upper arm of 11 patients with diffuse SSc (clinically uninvolved skin) and 8 age- and sex-matched control subjects. Dermal arterioles were dissected from the biopsy sample and mounted in a myograph for continuous monitoring of arteriolar diameter. The resting internal diameter of control and SSc arterioles was similar (mean +/- SEM 164+/-15 micro and 166+/-18micro, respectively).
RESULTS: Dermal arterioles displayed no spontaneous constrictor activity in the absence of stimulation. Vasoconstriction in response to KCI, a receptor-independent activator of smooth muscle, or to phenylephrine, a selective alpha1-adrenergic receptor (alpha1-AR) agonist, was similar in control and SSc arterioles. However, constrictor responses to UK 14,304, a selective alpha2-AR agonist, were increased in SSc compared with control arterioles (maximal constriction responses of 25+/-5% and 67+/-4% [mean +/- SEM] in control and SSc arterioles, respectively; P = 0.000014). Mechanical denudation of the endothelium did not alter reactivity to alpha2-AR activation, indicating that the enhanced constriction in SSc was not mediated by changes in endothelial dilator activity. Indeed, in arterioles constricted with phenylephrine, the endothelial stimuli acetylcholine or bradykinin evoked endothelium-dependent relaxation that was similar in control and SSc arterioles.
CONCLUSIONS: Vascular smooth muscle in SSc arterioles displayed a selective increase in alpha2-AR reactivity. The endothelial dilator function appeared normal. Altered activity of smooth muscle alpha2-ARs may contribute to the vasospastic activity that is a prominent feature of the SSc disease process.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10943881     DOI: 10.1002/1529-0131(200008)43:8<1886::AID-ANR27>3.0.CO;2-S

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

2.  Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.

Authors:  Andrea Fava; Peter K Wung; Fredrick M Wigley; Laura K Hummers; Natalie R Daya; Sharon R Ghazarian; Francesco Boin
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-01-24       Impact factor: 4.794

Review 3.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 4.  A vascular mechanistic approach to understanding Raynaud phenomenon.

Authors:  Nicholas A Flavahan
Journal:  Nat Rev Rheumatol       Date:  2014-12-23       Impact factor: 20.543

5.  Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.

Authors:  J Fowler; M Jarratt; A Moore; K Meadows; A Pollack; M Steinhoff; Y Liu; M Leoni
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

Review 6.  Rap1 GTPases: an emerging role in the cardiovasculature.

Authors:  Selvi C Jeyaraj; Nicholas T Unger; Maqsood A Chotani
Journal:  Life Sci       Date:  2011-02-02       Impact factor: 5.037

Review 7.  Evaluation and management of pulmonary fibrosis in scleroderma.

Authors:  Barbara White
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

Review 8.  A Narrative Review of Pathogenetic and Histopathologic Aspects, Epidemiology, Classification Systems, and Disease Outcome Measures in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Silvia Piantoni; Fabrizio Angeli; Stefania Bertocchi; Franco Franceschini; Paolo Airò
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-07       Impact factor: 10.817

Review 9.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

10.  Treatment of Raynaud's phenomenon: new insights and developments.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.